1099 related articles for article (PubMed ID: 31111345)
1. Changes in APRI and FIB-4 in HBeAg-negative treatment-naive chronic hepatitis B patients with significant liver histological lesions receiving 5-year entecavir therapy.
Liu R; Guo J; Lu Y; Zhang L; Shen G; Wu S; Chang M; Hu L; Hao H; Li M; Xie Y
Clin Exp Med; 2019 Aug; 19(3):309-320. PubMed ID: 31111345
[TBL] [Abstract][Full Text] [Related]
2. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
3. Changes of FibroScan, APRI, and FIB-4 in chronic hepatitis B patients with significant liver histological changes receiving 3-year entecavir therapy.
Li Q; Chen L; Zhou Y
Clin Exp Med; 2018 May; 18(2):273-282. PubMed ID: 29350286
[TBL] [Abstract][Full Text] [Related]
4. Assessing significant fibrosis using imaging-based elastography in chronic hepatitis B patients: Pilot study.
Park HS; Choe WH; Han HS; Yu MH; Kim YJ; Jung SI; Kim JH; Kwon SY
World J Gastroenterol; 2019 Jul; 25(25):3256-3267. PubMed ID: 31333316
[TBL] [Abstract][Full Text] [Related]
5. Acoustic Radiation Force Impulse Elastography with APRI and FIB-4 to Identify Significant Liver Fibrosis in Chronic Hepatitis B Patients.
Tseng CH; Chang CY; Mo LR; Lin JT; Tai CM; Perng DS; Lin CW; Hsu YC
Ann Hepatol; 2018 Aug; 17(5):789-794. PubMed ID: 30145564
[TBL] [Abstract][Full Text] [Related]
6. Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B.
Hu YC; Liu H; Liu XY; Ma LN; Guan YH; Luo X; Ding XC
World J Gastroenterol; 2017 Nov; 23(41):7425-7432. PubMed ID: 29151696
[TBL] [Abstract][Full Text] [Related]
7. Histological outcome for chronic hepatitis B patients treated with entecavir vs lamivudine-based therapy.
Wang JL; Du XF; Chen SL; Yu YQ; Wang J; Hu XQ; Shao LY; Chen JZ; Weng XH; Zhang WH
World J Gastroenterol; 2015 Aug; 21(32):9598-606. PubMed ID: 26327767
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study.
Li Q; Ren X; Lu C; Li W; Huang Y; Chen L
Medicine (Baltimore); 2017 Mar; 96(12):e6336. PubMed ID: 28328813
[TBL] [Abstract][Full Text] [Related]
9. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China.
Li Q; Li W; Huang Y; Chen L
J Viral Hepat; 2016 Nov; 23(11):912-919. PubMed ID: 27375134
[TBL] [Abstract][Full Text] [Related]
10. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B.
Liu DP; Lu W; Zhang ZQ; Wang YB; Ding RR; Zhou XL; Huang D; Li XF
J Viral Hepat; 2018 May; 25(5):581-589. PubMed ID: 29230907
[TBL] [Abstract][Full Text] [Related]
11. APRI, the FIB-4 score, and Forn's index have noninvasive diagnostic value for liver fibrosis in patients with chronic hepatitis B.
Ucar F; Sezer S; Ginis Z; Ozturk G; Albayrak A; Basar O; Ekiz F; Coban S; Yuksel O; Armutcu F; Akbal E
Eur J Gastroenterol Hepatol; 2013 Sep; 25(9):1076-81. PubMed ID: 23510962
[TBL] [Abstract][Full Text] [Related]
12. Does regression in treatment-induced liver fibrosis reflect noninvasive tests? Assessing treatment results of hepatitis B patients who took potent antiviral drugs for 5 years.
Yalaki S; Yalcin MS
Niger J Clin Pract; 2020 Feb; 23(2):226-231. PubMed ID: 32031098
[TBL] [Abstract][Full Text] [Related]
13. Stepwise application of fibrosis index based on four factors, red cell distribution width-platelet ratio, and aspartate aminotransferase-platelet ratio for compensated hepatitis B fibrosis detection.
Chen YP; Hu XM; Liang XE; Huang LW; Zhu YF; Hou JL
J Gastroenterol Hepatol; 2018 Jan; 33(1):256-263. PubMed ID: 28452125
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of prolonged entecavir monotherapy in treatment-naïve chronic hepatitis B patients exhibiting a partial virologic response to entecavir.
Choi HN; Song JE; Lee HC; Jo HH; Lee CH; Kim BS
Clin Mol Hepatol; 2015 Mar; 21(1):24-31. PubMed ID: 25834799
[TBL] [Abstract][Full Text] [Related]
15. The Easy Liver Fibrosis Test (eLIFT) for predicting advanced liver fibrosis in patients with chronic hepatitis B.
Wang J; Chen Z; Yan X; Yang Y; Liu Y; Chen Y; Jia B; Xia J; Xiong Y; Zhang Z; Ding W; Huang R; Wu C
Discov Med; 2019 Sep; 28(153):149-158. PubMed ID: 31926586
[TBL] [Abstract][Full Text] [Related]
16. AST/ALT ratio, APRI, and FIB-4 compared to FibroScan for the assessment of liver fibrosis in patients with chronic hepatitis B in Bandar Abbas, Hormozgan, Iran.
Moosavy SH; Eftekhar E; Davoodian P; Nejatizadeh A; Shadman M; Zare S; Nazarnezhad MA
BMC Gastroenterol; 2023 May; 23(1):145. PubMed ID: 37170243
[TBL] [Abstract][Full Text] [Related]
17. Effect of Entecavir and Tenofovir Treatment on Noninvasive Fibrosis Scores: Which One Is Better?
Koksal AR; Alkim H; Boga S; Ergun M; Bayram M; Ozguven BY; Alkim C
Am J Ther; 2016; 23(2):e429-38. PubMed ID: 25650531
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients.
Kim WR; Berg T; Asselah T; Flisiak R; Fung S; Gordon SC; Janssen HL; Lampertico P; Lau D; Bornstein JD; Schall RE; Dinh P; Yee LJ; Martins EB; Lim SG; Loomba R; Petersen J; Buti M; Marcellin P
J Hepatol; 2016 Apr; 64(4):773-80. PubMed ID: 26626497
[TBL] [Abstract][Full Text] [Related]
19. [Predictive value of liver pathologic changes in determining the effectiveness of entecavir treatment for chronic hepatitis B-An analysis of 1 366 cases].
Sun MM; Zhang W; Chen G; An Y; Wang YQ; Shang QH
Zhonghua Yi Xue Za Zhi; 2017 Apr; 97(15):1160-1164. PubMed ID: 28427123
[No Abstract] [Full Text] [Related]
20. Long-term effects of entecavir and tenofovir treatment on the fibrotic burden in patients with chronic hepatitis B.
Chon YE; Kim SU; Seo YS; Lee HW; Lee HA; Kim MN; Roh YH; Park JY; Kim DY; Ahn SH; Tak WY; Park SY; Kim BK
J Gastroenterol Hepatol; 2022 Jan; 37(1):200-207. PubMed ID: 34478195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
